Answers are grounded in this paper and cite their sources.
In severely head-injured children, diffuse brain swelling is the most common initial computed tomography (CT) scan finding [1-3]. Diffuse brain swelling is associated with long periods of increased intracranial pressure (ICP), poor neurologic outcome, and a high mortality rate in children [2,4]. Uncontrollable increased ICP remains the main cause of death in patients with severe traumatic brain injury [5,6]. The efficacy of common nonsurgical treatments of increased ICP has been questioned [7-9]. There are experimental and clinical data suggesting that dihydroergotamine (DHE), a cerebral vasoconstrictor, may reduce increased ICP [5,10,11], but there are very few studies in children [10]. We present a case of a patient in whom all standard nonsurgical treatments failed to reduced posttraumatic increased ICP due to diffuse brain swelling and in whom DHE was successful. Case Report A 5-yr-old girl sustained a head injury after a high-speed pedestrian/motor vehicle accident. On first clinical examination by a field physician, she was found to be comatose, with a Glasgow Coma Scale score of 6 and a Pediatric Trauma Score of -4 [12]. Despite aggressive prehospital care, including field endotracheal intubation (after sedation with thiopental 3 mg/kg in divided doses), mechanical ventilation, and fluid therapy, the patient was hemodynamically unstable on arrival in the emergency room, with a blood pressure of 54/32 mm Hg and a heart rate of 135 bpm). Chest radiographs showed normal pulmonary parenchyma, a sternal fracture, and a fractured right clavicle. A brain CT scan performed after initial stabilization and approximately 2 h after injury showed diffuse brain swelling (compressed mesencephalic cisterns, reduced ventricular size without midline shift or intraparenchymal hemmorhages) [2], an open frontal depressed skull fracture without evidence of parenchymal injury, and a fracture of the right orbit. No other injuries were noted on completion of the clinical and radiological examinations. The hemogloblin value, white blood cell count, and platelet count were 5.6 g/dL, 15.5 cells/mm3, and 232,000/mm (3), respectively. The low hemoglobin value was related to bleeding from the scalp and depressed skull fracture. Prothrombin time was prolonged, with decreased levels of factor II (39%), factor V (40%), and factor VII+X (53%). Electrolyte values were normal, except for the blood glucose level, which was increased (2.4 mg/dL). An ICP monitoring device (Neuro Monitor MicroSensor Kit; Codman & Shurtleff, Inc, Randolph, MA) was inserted, and the initial basal value of ICP was 15 mm Hg. After reduction of the depressed skull fracture by a pediatric neurosurgeon, the patient was transferred to the neurosurgical intensive care unit. Initial treatment included sedation (flunitrazepam/fentanyl), moderate hyperventilation (PaCO2 32 mm Hg), dopamine to maintain cerebral perfusion pressure (CPP) over 50 mm Hg, and osmotherapy (mannitol/furosemide) as needed to maintain an ICP less than 15 mm Hg. Continuous monitoring of jugular venous oxygen saturation (Svjo2) was used to optimize treatment, maintaining the Svjo2 between 65% and 75%. The patient was maintained on a negative fluid balance, and hypovolemia was avoided by using albumin and blood transfusion. On Day 3, osmotherapy was discontinued because of a serum sodium level of 155 mmol/L and a serum osmolality of 317 mOsm/kg. On Day 4, despite aggressive hyperventilation (PaCO2 21 mm Hg) and thiopental-induced burst suppression, Svjo2 values remained increased (>80%), suggesting cerebral hyperemia. DHE administrated at bolus dose of 3 micro g/kg, immediately followed by an intravenous infusion of 1.2 micro g [center dot] kg-1 [center dot] h-1, induced a dramatic decrease of both ICP (from 42 to 20 mm Hg) and Svjo2 (from 85% to 75%) (Figure 1 and Figure 2). Initial dose and maintenance doses were selected based on the study of Asgeirsson et al. [10]. Although DHE produced a transient decrease in mean arterial pressure, a more significant decrease in ICP was observed, resulting in an overall improvement of CPP. Thereafter, ICP stabilized at a level below 20 mm Hg, whereas Svjo2 values were between 70% and 75%. Thiopental and dopamine infusions were discontinued on Day 6. On Day 7, the DHE infusion was gradually decreased, then discontinued without rebound intracranial hypertension. On Day 10, sedation was discontinued, and the patient progressively improved neurologically, with spontaneous movement of the four limbs noted on Day 11. CT scan at this time showed an improvement, with normal ventricular and mesencephalic cistern size. The patient was successfully weaned from the ventilator on Day 13. On Day 19 she was fully awake, with a residual right hemiparesis. On Day 21 she underwent surgery for maxillofacial plastic surgery. She was discharged to a rehabilitation center on Day 30 and was is in good heath, with a Glasgow Outcome Scale score of 4 on routine follow-up 6 mo later [13].Figure 1: Effects of the injection of a bolus dose of dihydroergotamine (DHE) on jugular venous oxygen saturation (Svjo2), ICP (intracranial pressure), and invasive arterial pressure. SAP = systolic arterial pressure, MAP = mean arterial pressure, DAP = diastolic arterial pressure.Figure 2: Changes in heart rate (HR), mean arterial pressure (MAP), intracranial pressure (ICP), cerebral perfusion pressure (CPP), and jugular venous oxygen saturation (Svjo2) during the first 36 h of therapy with dihydroergotamine (DHE).Discussion This case illustrates the potential usefulness of DHE when all conventional therapies fail to reduce intracranial hypertension. In this case, the patient developed uncontrollable intracranial hypertension associated with an elevated Svjo2, despite conventional treatment. DHE induced a dramatic decrease of both ICP and Svjo (2). Our patient made a good recovery, despite the high risk of poor outcome and mortality because of diffuse brain swelling [3]. The use of DHE to treat severe posttraumatic intracranial hypertension has been reported in small series of patients [10,11]. In a study by Asgeirsson et al. [11], DHE in association with hypotensive treatment was successfully used in patients with extremely poor prognostic outcome [10,11]. In traumatic brain injury, the blood-brain barrier is more permeable, and brain edema is the predominant cause of increased ICP. The efficacy of DHE is based on reduction of increased capillary pressure through precapillary vasoconstriction in the presence of a mild reduction in blood pressure using beta-blockade and the patient in a negative fluid balance. However, this approach is still controversial [14]. The main point of controversy is related to the administration of hypotensive drugs to severely head-injured patients. To most clinicians, active hypotensive therapy has not become part of treatment of posttraumatic brain edema. On the contrary, a high perfusion pressure is still recommended and considered crucial to ensure adequate cerebral blood flow and cerebral oxygenation, and inotropic support is often given [15,16]. We did not administer hypotensive therapy but instead infused dopamine to maintain CPP over 50 mm Hg. Moreover, even if CPP remains constant but both blood pressure and ICP decrease, there may be a reduction in cerebral blood flow if autoregulation is impaired [17], contributing to cerebral ischemia. Continuous monitoring of Svjo2 is valuable in this situation and was used in our patient. Values of more than 75% for Svjo2 indicate hyperemia, in which induced vasoconstriction is beneficial [13], which was the case in our patient. On the other hand, Svjo2 values of less than 50% indicate global brain ischemia, and attempts to induce cerebral vasoconstriction are likely to be harmful [18,19] and should be considered as contraindicated. DHE has complicated effects as partial agonist/antagonist at multiple receptor sites. Despite these complicated actions, no serious adverse effects have been reported when DHE was used to treat uncontrollable increased ICP after head trauma, except for one case of gangrene and renal failure [20]. For all potent vasoactive drugs, such as DHE, the therapeutic aim is to give the optimal dose, which is the lowest effective dose associated with limited side effects. The dose used in our patient corresponded to the total maximal dose of DHE recommended by others for the treatment of increased ICP [4,9,10]. In summary, this case report suggests that DHE may reduce uncontrollably increased ICP when conventional therapy fails. Although this new therapy seems promising in the case of uncontrollable posttraumatic increased ICP, further studies are needed to validate our observations.
No takes yet. Share an insight, caveat, or question.
Orliaguet et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: